| Identification | Back Directory | [Name]
(-)-MDL 100907 | [CAS]
175673-57-1 | [Synonyms]
M 100009
MDL 100009
(S)-MDL 100907
MDL 100009 - MDL 100907, (S)-(-)-
4-Piperidinemethanol, α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-, (αS)-
4-PIPERIDINEMETHANOL, A-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-, (AS)-
(S)-(2,3-DIMETHOXY-PHENYL)-(1-[2-(4-FLUORO-PHENYL)-ETHYL]-PIPERIDIN-4-YL)-METHANOL | [Molecular Formula]
C22H28FNO3 | [MDL Number]
MFCD10565916 | [MOL File]
175673-57-1.mol | [Molecular Weight]
373.465 |
| Chemical Properties | Back Directory | [Boiling point ]
499.4±45.0 °C(Predicted) | [density ]
1.150±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [pka]
13.93±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
(S)-Volinanserin is an isform of Volinanserin (HY-14940). Volinanserin is a potent and selective antagonist of 5-HT2 receptor, with a Ki of 0.36 nM, and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 and DA D2 receptors. Volinanserin has antipsychotic activity. | [in vivo]
Volinanserin (MDL 100907; 0.008-2.0 mg/kg, i.p.) significantly decreases d-amphetamine-stimulated locomotor activity in mice, with an ED50 of 0.3 mg/kg, but shows no obvious reduction in the base-line locomotor activity in mice. Volinanserin produces atalepsy with an ED50 of 10-50 mg/kg in rats. Volinanserin does not reduces apomorphine-induced stereotypies or produces catalepsy in rats[1]. Volinanserin (M100907) combined with MK-801 significantly decreases reinforcers at 1 μg/kg, but dose-dependently (10, 100 μg/kg) antagonizes the disruptive effect of MK-801 in rats via i.p. administration. Volinanserin (6.25 μg/kg) enhances the antidepressant-like action of Desipramine (HY-B1272A) in rats performing under a DRL 72-s schedule, and elevates the antidepressant-like effect of Tranylcypromine (HY-17447)[2]. | [References]
[1] Sorensen SM, et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther. 1993 Aug;266(2):684-91. PMID:8102646
[2] Ardayfio PA, et al. The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther. 2008 Dec;327(3):891-7. DOI:10.1124/jpet.108.143370 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|